Protalix Reports Positive Topline Results for Phase III Data
Protalix BioTherapeutics Inc. (PLX) announced positive topline data from Phase III BRIDGE clinical trial of its lead drug candidate PRX-102. This Phase III study was an open label, single arm switch-over 12 month long study aiming to evaluate the safety and efficacy of pegunigalsidase alfa, 1 mg/kg infused every two weeks, in Fabry patients previously treated with agalsidase alfa, for at least two years and on a stable dose for at least six months. The data showed substantial improvement in renal function in both